Efficacy of Bortezomib, Cyclophosphamide and Dexamethasone in Treatment Naive Patients with High Risk Cardiac AL Amyloidosis (Mayo Clinic stage III)

- Plasmocytes → Free light chain deposits → Amyloid cardiopathy

- NT-proBNP < 9500 ng/L
  - Bortezomib
  - Cyclophosphamide
  - Dexamethasone

- NT-proBNP > 9500 ng/L
  - 4.4 months median survival

- Earlier diagnosis and treatment mandatory to improve survival!

81% survival at 1 year

Jaccard et al., Haematologica, 2014